A citation-based method for searching scientific literature

Avivit Cahn, Itamar Raz, Lawrence A Leiter, Ofri Mosenzon, Sabina A Murphy, Erica L Goodrich, Ilan Yanuv, Aliza Rozenberg, Deepak L Bhatt, Darren K McGuire, John P H Wilding, Ingrid A M Gause-Nilsson, Anna Maria Langkilde, Marc S Sabatine, Stephen D Wiviott. Diabetes Care 2021
Times Cited: 2







List of co-cited articles
2 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Worldwide inertia to the use of cardiorenal protective glucose-lowering drugs (SGLT2i and GLP-1 RA) in high-risk patients with type 2 diabetes.
Guntram Schernthaner, Naim Shehadeh, Alexander S Ametov, Anna V Bazarova, Fahim Ebrahimi, Peter Fasching, Andrej Janež, Péter Kempler, Ilze Konrāde, Nebojša M Lalić,[...]. Cardiovasc Diabetol 2020
12
100

Interpreting the results of the VERTIS-CV trial: Is this the end of the "class effect" perspective?
Theocharis Koufakis, Nikolaos Papanas, George Dimitriadis, Pantelis Zebekakis, Kalliopi Kotsa. J Diabetes 2020
5
100

Changes in SGLT2i and GLP-1RA real-world initiator profiles following cardiovascular outcome trials: A Danish nationwide population-based study.
Jakob S Knudsen, Lisbeth M Baggesen, Maria Lajer, Larisa Nurkanovic, Anastasia Ustyugova, Henrik T Sørensen, Reimar W Thomsen. PLoS One 2020
11
50



Thiazolidinediones: the Forgotten Diabetes Medications.
Harold E Lebovitz. Curr Diab Rep 2019
32
50

Pharmacogenetics of the Glucagon-like Peptide-1 Receptor Agonist Liraglutide: A Step Towards Personalized Type 2 Diabetes Management.
Artemis Kyriakidou, Theocharis Koufakis, Dimitrios G Goulis, Yiannis Vasilopoulos, Pantelis Zebekakis, Kalliopi Kotsa. Curr Pharm Des 2021
2
50


Sodium-Glucose Cotransporter 2 Inhibition for the Prevention of Cardiovascular Events in Patients With Type 2 Diabetes Mellitus: A Systematic Review and Meta-Analysis.
Clare Arnott, Qiang Li, Amy Kang, Brendon L Neuen, Severine Bompoint, Carolyn S P Lam, Anthony Rodgers, Kenneth W Mahaffey, Christopher P Cannon, Vlado Perkovic,[...]. J Am Heart Assoc 2020
62
50

Real-World Adherence and Discontinuation of Glucagon-Like Peptide-1 Receptor Agonists Therapy in Type 2 Diabetes Mellitus Patients in the United States.
Tracey Weiss, Richard D Carr, Sampriti Pal, Lingfeng Yang, Baanie Sawhney, Robert Boggs, Swapnil Rajpathak, Kristy Iglay. Patient Prefer Adherence 2020
2
50

2019 Update to: Management of Hyperglycemia in Type 2 Diabetes, 2018. A Consensus Report by the American Diabetes Association (ADA) and the European Association for the Study of Diabetes (EASD).
John B Buse, Deborah J Wexler, Apostolos Tsapas, Peter Rossing, Geltrude Mingrone, Chantal Mathieu, David A D'Alessio, Melanie J Davies. Diabetes Care 2020
290
50

Empagliflozin as add-on to metformin in patients with type 2 diabetes: a 24-week, randomized, double-blind, placebo-controlled trial.
Hans-Ulrich Häring, Ludwig Merker, Elke Seewaldt-Becker, Marc Weimer, Thomas Meinicke, Uli C Broedl, Hans J Woerle. Diabetes Care 2014
250
50

Sodium-Glucose Cotransporter-2 Inhibitors in Nephrology Practice: A Narrative Review.
Lisa Dubrofsky, Anand Srivastava, David Z Cherney. Can J Kidney Health Dis 2020
3
50

Cardiovascular, mortality, and kidney outcomes with GLP-1 receptor agonists in patients with type 2 diabetes: a systematic review and meta-analysis of cardiovascular outcome trials.
Søren L Kristensen, Rasmus Rørth, Pardeep S Jhund, Kieran F Docherty, Naveed Sattar, David Preiss, Lars Køber, Mark C Petrie, John J V McMurray. Lancet Diabetes Endocrinol 2019
319
50


Patterns of glucose-lowering medication use in patients with type 2 diabetes and heart failure. Insights from the Diabetes Collaborative Registry (DCR).
Suzanne V Arnold, Justin B Echouffo-Tcheugui, Carolyn S P Lam, Silvio E Inzucchi, Fengming Tang, Darren K McGuire, Abhinav Goyal, Thomas M Maddox, Laurence S Sperling, Gregg C Fonarow,[...]. Am Heart J 2018
14
50

Cardiovascular Risk Reduction With Liraglutide: An Exploratory Mediation Analysis of the LEADER Trial.
John B Buse, Stephen C Bain, Johannes F E Mann, Michael A Nauck, Steven E Nissen, Stuart Pocock, Neil R Poulter, Richard E Pratley, Martin Linder, Tea Monk Fries,[...]. Diabetes Care 2020
19
50

Self-reported Barriers to Adherence and Persistence to Treatment With Injectable Medications for Type 2 Diabetes.
C Victor Spain, Jonathon J Wright, Rebecca M Hahn, Ashley Wivel, Alan A Martin. Clin Ther 2016
35
50

Comparative Effectiveness of Glucose-Lowering Drugs for Type 2 Diabetes: A Systematic Review and Network Meta-analysis.
Apostolos Tsapas, Ioannis Avgerinos, Thomas Karagiannis, Konstantinos Malandris, Apostolos Manolopoulos, Panagiotis Andreadis, Aris Liakos, David R Matthews, Eleni Bekiari. Ann Intern Med 2020
27
50

Primary care detection of chronic kidney disease in adults with type-2 diabetes: the ADD-CKD Study (awareness, detection and drug therapy in type 2 diabetes and chronic kidney disease).
Lynda A Szczech, Rebecca C Stewart, Hsu-Lin Su, Richard J DeLoskey, Brad C Astor, Chester H Fox, Peter A McCullough, Joseph A Vassalotti. PLoS One 2014
45
50

Health care resource utilization and cost of severe hypoglycemia treatment in insulin-treated patients with diabetes in the United States.
Sanjay Bajpai, Siew Wong-Jacobson, Dongju Liu, Beth Mitchell, Ginger Haynes, Kristen Syring, Ayad K Ali, Chanadda Chinthammit. J Manag Care Spec Pharm 2021
1
100

Dulaglutide and cardiovascular outcomes in type 2 diabetes (REWIND): a double-blind, randomised placebo-controlled trial.
Hertzel C Gerstein, Helen M Colhoun, Gilles R Dagenais, Rafael Diaz, Mark Lakshmanan, Prem Pais, Jeffrey Probstfield, Jeffrey S Riesmeyer, Matthew C Riddle, Lars Rydén,[...]. Lancet 2019
597
50

Dapagliflozin and Cardiovascular Outcomes in Type 2 Diabetes.
Stephen D Wiviott, Itamar Raz, Marc P Bonaca, Ofri Mosenzon, Eri T Kato, Avivit Cahn, Michael G Silverman, Thomas A Zelniker, Julia F Kuder, Sabina A Murphy,[...]. N Engl J Med 2019
50

Dapagliflozin in Patients with Chronic Kidney Disease.
Hiddo J L Heerspink, Bergur V Stefánsson, Ricardo Correa-Rotter, Glenn M Chertow, Tom Greene, Fan-Fan Hou, Johannes F E Mann, John J V McMurray, Magnus Lindberg, Peter Rossing,[...]. N Engl J Med 2020
370
50

The effect of canagliflozin on amputation risk in the CANVAS program and the CREDENCE trial.
Clare Arnott, Yuli Huang, Brendon L Neuen, Gian Luca Di Tanna, Christopher P Cannon, Richard Oh, Robert Edwards, Mary Kavalam, Norman Rosenthal, Vlado Perkovic,[...]. Diabetes Obes Metab 2020
6
50

RS1 (Rsc1A1) deficiency limits cerebral SGLT1 expression and delays brain damage after experimental traumatic brain injury.
Anne Sebastiani, Frederik Greve, Christina Gölz, Carola Y Förster, Hermann Koepsell, Serge C Thal. J Neurochem 2018
5
50

Dual SGLT-1 and SGLT-2 inhibition improves left atrial dysfunction in HFpEF.
David Bode, Lukas Semmler, Paulina Wakula, Niklas Hegemann, Uwe Primessnig, Nicola Beindorff, David Powell, Raphael Dahmen, Hartmut Ruetten, Christian Oeing,[...]. Cardiovasc Diabetol 2021
4
50

Canagliflozin and Renal Outcomes in Type 2 Diabetes and Nephropathy.
Vlado Perkovic, Meg J Jardine, Bruce Neal, Severine Bompoint, Hiddo J L Heerspink, David M Charytan, Robert Edwards, Rajiv Agarwal, George Bakris, Scott Bull,[...]. N Engl J Med 2019
50

Localization of the Na+-D-glucose cotransporter SGLT1 in the blood-brain barrier.
Katrin Elfeber, Alwin Köhler, Michael Lutzenburg, Christina Osswald, Hans-Joachim Galla, Otto W Witte, Hermann Koepsell. Histochem Cell Biol 2004
59
50

Dapagliflozin in Patients with Heart Failure and Reduced Ejection Fraction.
John J V McMurray, Scott D Solomon, Silvio E Inzucchi, Lars Køber, Mikhail N Kosiborod, Felipe A Martinez, Piotr Ponikowski, Marc S Sabatine, Inder S Anand, Jan Bělohlávek,[...]. N Engl J Med 2019
50

Empagliflozin and Cerebrovascular Events in Patients With Type 2 Diabetes Mellitus at High Cardiovascular Risk.
Bernard Zinman, Silvio E Inzucchi, John M Lachin, Christoph Wanner, David Fitchett, Sven Kohler, Michaela Mattheus, Hans J Woerle, Uli C Broedl, Odd Erik Johansen,[...]. Stroke 2017
72
50

Sotagliflozin in Patients with Diabetes and Chronic Kidney Disease.
Deepak L Bhatt, Michael Szarek, Bertram Pitt, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Silvio E Inzucchi, Mikhail N Kosiborod,[...]. N Engl J Med 2021
83
50

Sotagliflozin in Patients with Diabetes and Recent Worsening Heart Failure.
Deepak L Bhatt, Michael Szarek, P Gabriel Steg, Christopher P Cannon, Lawrence A Leiter, Darren K McGuire, Julia B Lewis, Matthew C Riddle, Adriaan A Voors, Marco Metra,[...]. N Engl J Med 2021
141
50

Cardiovascular and Renal Outcomes with Empagliflozin in Heart Failure.
Milton Packer, Stefan D Anker, Javed Butler, Gerasimos Filippatos, Stuart J Pocock, Peter Carson, James Januzzi, Subodh Verma, Hiroyuki Tsutsui, Martina Brueckmann,[...]. N Engl J Med 2020
492
50

Stroke paradox with SGLT-2 inhibitors: a play of chance or a viscosity-mediated reality?
Konstantinos P Imprialos, Chrysoula Boutari, Konstantinos Stavropoulos, Michael Doumas, Asterios I Karagiannis. J Neurol Neurosurg Psychiatry 2017
26
50

Canagliflozin and Cardiovascular and Renal Events in Type 2 Diabetes.
Bruce Neal, Vlado Perkovic, Kenneth W Mahaffey, Dick de Zeeuw, Greg Fulcher, Ngozi Erondu, Wayne Shaw, Gordon Law, Mehul Desai, David R Matthews. N Engl J Med 2017
50

Empagliflozin, Cardiovascular Outcomes, and Mortality in Type 2 Diabetes.
Bernard Zinman, Christoph Wanner, John M Lachin, David Fitchett, Erich Bluhmki, Stefan Hantel, Michaela Mattheus, Theresa Devins, Odd Erik Johansen, Hans J Woerle,[...]. N Engl J Med 2015
50

The use of sodium-glucose co-transporter 2 inhibitors in the inpatient setting: Is the risk worth taking?
Theocharis Koufakis, Omar G Mustafa, Ramzi A Ajjan, Xavier Garcia-Moll, Pantelis Zebekakis, George Dimitriadis, Kalliopi Kotsa. J Clin Pharm Ther 2020
10
50

What does sodium-glucose co-transporter 1 inhibition add: Prospects for dual inhibition.
Jessica A Dominguez Rieg, Timo Rieg. Diabetes Obes Metab 2019
18
50

Glycemic management in ESRD and earlier stages of CKD.
Mark E Williams, Rajesh Garg. Am J Kidney Dis 2014
48
50


The role of the kidneys in glucose homeostasis: a new path towards normalizing glycaemia.
R A DeFronzo, J A Davidson, S Del Prato. Diabetes Obes Metab 2012
316
50

SGLT2 Inhibitors in Type 2 Diabetes Management: Key Evidence and Implications for Clinical Practice.
John Wilding, Kevin Fernando, Nicola Milne, Marc Evans, Amar Ali, Steve Bain, Debbie Hicks, June James, Philip Newland-Jones, Dipesh Patel,[...]. Diabetes Ther 2018
26
50

Association of SGLT2 Inhibitors With Cardiovascular and Kidney Outcomes in Patients With Type 2 Diabetes: A Meta-analysis.
Darren K McGuire, Weichung J Shih, Francesco Cosentino, Bernard Charbonnel, David Z I Cherney, Samuel Dagogo-Jack, Richard Pratley, Michelle Greenberg, Shuai Wang, Susan Huyck,[...]. JAMA Cardiol 2021
51
50

Efficacy and safety of canagliflozin in patients with type 2 diabetes and stage 3 nephropathy.
Hala Yamout, Vlado Perkovic, Melanie Davies, Vincent Woo, Dick de Zeeuw, Cristiana Mayer, Ujjwala Vijapurkar, Irina Kline, Keith Usiskin, Gary Meininger,[...]. Am J Nephrol 2014
76
50

SGLT1 inhibition: Pros and cons.
Vasilis Tsimihodimos, Sebastien Filippas-Ntekouan, Moses Elisaf. Eur J Pharmacol 2018
14
50


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.